What is Elevian?
Founded in 2017 and headquartered in Allston, Massachusetts, Elevian is an emerging biotech enterprise dedicated to the development of medicines that restore the body's natural regenerative capacity. The company's core focus lies in identifying and harnessing proteins that decline with age, with the ultimate goal of treating a wide spectrum of age-related diseases. By targeting the fundamental biological mechanisms of aging, Elevian is carving out a distinct market position within the high-growth longevity and therapeutic innovation sectors. Their research-driven model seeks to move beyond symptomatic treatment, aiming instead to reverse the underlying physiological decline that characterizes many chronic health conditions.
How much funding has Elevian raised?
Elevian has raised a total of $55M across 2 funding rounds:
Angel/Seed
$15M
Series A
$40M
Angel/Seed (2020): $15M with participation from Longevity Fund companies, Western Technology Investment, BOLD Capital Partners, For Good Ventures, SavEarth Fund, Lauder Partners, Kizoo Ventures, and Prime Movers Lab
Series A (2021): $40M led by Prime Movers Lab, BOLD Capital Group, John A Kuelbs Family Office, and Leslie Ventures
Key Investors in Elevian
Prime Movers Lab
Prime Movers Lab is a venture capital firm that focuses on funding breakthrough scientific startups aimed at transforming industries and improving lives.
Longevity Fund
The Longevity Fund is a venture capital firm established in 2011, focused on funding companies that develop drugs for age-related diseases and longevity.
Western Technology Investment
Western Technology Investment specializes in providing venture debt to assist startups in financing their growth while minimizing shareholder dilution.
What's next for Elevian?
With the recent influx of capital, Elevian is well-positioned to transition its lead candidates through critical clinical milestones. The strategic focus for the coming quarters will likely involve expanding internal R&D capabilities and strengthening the intellectual property portfolio surrounding its regenerative protein therapies. As the company matures, the emphasis will shift toward establishing partnerships with larger pharmaceutical entities to facilitate large-scale clinical trials and eventual commercialization. The current funding environment suggests that Elevian is prepared to navigate the complexities of the biotech regulatory landscape while maintaining its commitment to radical innovation in the field of human longevity.
See full Elevian company page
